Literature DB >> 25556336

Rational design of a humanized glucagon-like peptide-1 receptor agonist antibody.

Yong Zhang1, Huafei Zou, Ying Wang, Dawna Caballero, Jose Gonzalez, Elizabeth Chao, Gus Welzel, Weijun Shen, Danling Wang, Peter G Schultz, Feng Wang.   

Abstract

Bovine antibody BLV1H12 possesses a unique "stalk-knob" architecture in its ultralong heavy chain CDR3, allowing substitutions of the "knob" domain with protein agonists to generate functional antibody chimeras. We have generated a humanized glucagon-like peptide-1 (GLP-1) receptor agonist antibody by first introducing a coiled-coil "stalk" into CDR3H of the antibody herceptin. Exendin-4 (Ex-4), a GLP-1 receptor agonist, was then fused to the engineered stalk with flexible linkers, and a Factor Xa cleavage site was inserted immediately in front of Ex-4 to allow release of the N-terminus of the fused peptide. The resulting clipped herceptin-Ex-4 fusion protein is more potent in vitro in activating GLP-1 receptors than the Ex-4 peptide. The clipped herceptin-Ex-4 has an extended plasma half-life of approximately four days and sustained control of blood glucose levels for more than a week in mice. This work provides a novel approach to the development of human or humanized agonist antibodies as therapeutics.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  antibodies; peptide; pharmacology; protein engineering; receptors

Mesh:

Substances:

Year:  2014        PMID: 25556336     DOI: 10.1002/anie.201410049

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  10 in total

1.  Generation of inhibitory monoclonal antibodies targeting matrix metalloproteinase-14 by motif grafting and CDR optimization.

Authors:  Dong Hyun Nam; Kuili Fang; Carlos Rodriguez; Tyler Lopez; Xin Ge
Journal:  Protein Eng Des Sel       Date:  2016-12-15       Impact factor: 1.650

2.  Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant.

Authors:  Rongsheng E Wang; Ying Wang; Yuhan Zhang; Chase Gabrelow; Yong Zhang; Victor Chi; Qiangwei Fu; Xiaozhou Luo; Danling Wang; Sean Joseph; Kristen Johnson; Arnab K Chatterjee; Timothy M Wright; Vân T B Nguyen-Tran; John Teijaro; Argyrios N Theofilopoulos; Peter G Schultz; Feng Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-23       Impact factor: 11.205

3.  Rational Design of Dual Agonist-Antibody Fusions as Long-acting Therapeutic Hormones.

Authors:  Yan Liu; Ying Wang; Yong Zhang; Tao Liu; Haiqun Jia; Huafei Zou; Qiangwei Fu; Yuhan Zhang; Lucy Lu; Elizabeth Chao; Holly Parker; Van Nguyen-Tran; Weijun Shen; Danling Wang; Peter G Schultz; Feng Wang
Journal:  ACS Chem Biol       Date:  2016-10-05       Impact factor: 5.100

4.  A humanized antibody inhibitor for cathepsin L.

Authors:  Xiaojing Shi; Yong Zhang
Journal:  Protein Sci       Date:  2020-08-07       Impact factor: 6.725

5.  Genetically Encoded Cholesterol-Modified Polypeptides.

Authors:  Davoud Mozhdehi; Kelli M Luginbuhl; Michael Dzuricky; Simone A Costa; Sinan Xiong; Fred C Huang; Mae M Lewis; Stephanie R Zelenetz; Christian D Colby; Ashutosh Chilkoti
Journal:  J Am Chem Soc       Date:  2019-01-04       Impact factor: 15.419

6.  Conservation and diversity in the ultralong third heavy-chain complementarity-determining region of bovine antibodies.

Authors:  Robyn L Stanfield; Ian A Wilson; Vaughn V Smider
Journal:  Sci Immunol       Date:  2016-07-14

7.  Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery.

Authors:  Peng-Yu Yang; Huafei Zou; Elizabeth Chao; Lance Sherwood; Vanessa Nunez; Michael Keeney; Esi Ghartey-Tagoe; Zhongli Ding; Herlinda Quirino; Xiaozhou Luo; Gus Welzel; Guohua Chen; Parminder Singh; Ashley K Woods; Peter G Schultz; Weijun Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-28       Impact factor: 11.205

8.  Rational Design of a Humanized Antibody Inhibitor of Cathepsin B.

Authors:  Zhefu Dai; Qinqin Cheng; Yong Zhang
Journal:  Biochemistry       Date:  2020-03-31       Impact factor: 3.162

9.  Functional GLP-1R antibodies identified from a synthetic GPCR-focused library demonstrate potent blood glucose control.

Authors:  Qiang Liu; Pankaj Garg; Burcu Hasdemir; Linya Wang; Emily Tuscano; Emily Sever; Erica Keane; Ana G Lujan Hernandez; Tom Z Yuan; Eric Kwan; Joyce Lai; Greg Szot; Sreenivasan Paruthiyil; Fumiko Axelrod; Aaron K Sato
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

10.  Mechanistic principles of an ultra-long bovine CDR reveal strategies for antibody design.

Authors:  Hristo L Svilenov; Julia Sacherl; Ulrike Protzer; Martin Zacharias; Johannes Buchner
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.